Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncology Drug Value Tools From NCCN, ASCO To Get Real-World Testing

This article was originally published in The Pink Sheet Daily

Executive Summary

Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.

You may also be interested in...



ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.

As Drug Value Frameworks Gain Traction, Patients Seek More Input

'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.

Medical Benefit, Hospital Drugs Exempt From Detailed Cost, Coverage Reporting In Final Rule

The most detailed US reporting requirements regarding prescription drug costs and coverage will target medicines reimbursed under the retail pharmacy benefit.

Topics

UsernamePublicRestriction

Register

PS078111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel